Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 3 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Peritoneal Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Liver, Cancer of, Primary Resectable 1 Hepatocellular Carcinoma Resectable 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Advanced Gastric Cancer 1

Interventions

Sorafenib 46 lenvatinib 44 apatinib 23 sintilimab 22 Fluorouracil 21 camrelizumab 20 Oxaliplatin 17 Radiofrequency Ablation 16 Radiosurgery 15 Hepatectomy 15 tislelizumab 14 Leucovorin 14 Radiotherapy 12 Doxorubicin 12 toripalimab 11 Folfox protocol 10 Bevacizumab 10 Immune Checkpoint Inhibitors 9 Epirubicin 9 regorafenib 8 Ethiodized Oil 8 durvalumab 7 donafenib 7 anlotinib 7 Neoadjuvant Therapy 7 pembrolizumab 6 entecavir 6 Surgical Procedures, Operative 6 Nivolumab 6 Injections 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Carcinoma, Hepatocellular × lobaplatin × Clear all

NCT02301091 2016-04-14

CORTT

Sun Yat-sen University

Phase 3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡